-
Je něco špatně v tomto záznamu ?
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
JS. Smolen, R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. van Vollenhoven, D. Aletaha, M. Aringer, M. Boers, CD. Buckley, F. Buttgereit, V. Bykerk, M. Cardiel, B. Combe, M. Cutolo, Y. van...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 1939-01-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 1939-01-01 do Před 6 měsíci
Family Health Database (ProQuest)
od 1939-01-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
- MeSH
- antirevmatika terapeutické užití MeSH
- časové faktory MeSH
- glukokortikoidy terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- Janus kinasy antagonisté a inhibitory MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- methotrexát terapeutické užití MeSH
- monoklonální protilátky terapeutické užití MeSH
- náhrada léků MeSH
- revmatoidní artritida farmakoterapie MeSH
- TNF-alfa antagonisté a inhibitory MeSH
- zapojení pacienta MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
5 A Nasonova Research Institute of Rheumatology Moscow Russian Federation
Centro de Investigación Clínica de Morelia SC Michoacán México
Department Medical Humanities VU Medical Centre Amsterdam The Netherlands
Department of Epidemiology and Biostatistics VU University Medical Center Amsterdam The Netherlands
Department of Medicine University of Queensland Queensland Australia
Department of Psychology Health and Technology University of Twente Enschede The Netherlands
Department of Rheumatology and Immunology Beijing University People's Hospital Beijing China
Department of Rheumatology Bernhoven Uden The Netherlands
Department of Rheumatology Diakonhjemmet Hospital Oslo Norway
Department of Rheumatology Leiden University Medical Center Leiden The Netherlands
Department of Rheumatology Sorbonne Universités Pitié Salpêtrière Hospital Paris France
Division of Rheumatology Department of Medicine 3 Medical University of Vienna Vienna Austria
Division of Rheumatology University Hospitals of Geneva Geneva Switzerland
Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands
Fundación Ramón Dominguez Hospital Clinico Universitario Santiago Spain
Institute of Rheumatology and Clinic of Rheumatology Charles University Prague Czech Republic
Keio University School of Medicine Keio University Hospital Tokyo Japan
National Institute of Rheumatology and Physiotherapy Semmelweis University Budapest Hungary
Organización Médica de Investigación Buenos Aires Argentina
Research Laboratory and Division of Clinical Rheumatology University of Genoa Genoa Italy
Rheumatology Department Karolinska Institute Stockholm Sweden
Rheumatology Department Lapeyronie Hospital Montpellier University UMR 5535 Montpellier France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030985
- 003
- CZ-PrNML
- 005
- 20171030103812.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/annrheumdis-2016-210715 $2 doi
- 035 __
- $a (PubMed)28264816
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Smolen, Josef S $u Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria.
- 245 10
- $a EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update / $c JS. Smolen, R. Landewé, J. Bijlsma, G. Burmester, K. Chatzidionysiou, M. Dougados, J. Nam, S. Ramiro, M. Voshaar, R. van Vollenhoven, D. Aletaha, M. Aringer, M. Boers, CD. Buckley, F. Buttgereit, V. Bykerk, M. Cardiel, B. Combe, M. Cutolo, Y. van Eijk-Hustings, P. Emery, A. Finckh, C. Gabay, J. Gomez-Reino, L. Gossec, JE. Gottenberg, JMW. Hazes, T. Huizinga, M. Jani, D. Karateev, M. Kouloumas, T. Kvien, Z. Li, X. Mariette, I. McInnes, E. Mysler, P. Nash, K. Pavelka, G. Poór, C. Richez, P. van Riel, A. Rubbert-Roth, K. Saag, J. da Silva, T. Stamm, T. Takeuchi, R. Westhovens, M. de Wit, D. van der Heijde,
- 520 9_
- $a Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a revmatoidní artritida $x farmakoterapie $7 D001172
- 650 _2
- $a náhrada léků $7 D057915
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a glukokortikoidy $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Janus kinasy $x antagonisté a inhibitory $7 D053612
- 650 _2
- $a methotrexát $x terapeutické užití $7 D008727
- 650 _2
- $a zapojení pacienta $7 D010358
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a TNF-alfa $x antagonisté a inhibitory $7 D014409
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Landewé, Robert $u Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands. Zuyderland Medical Center, Heerlen, The Netherlands.
- 700 1_
- $a Bijlsma, Johannes $u Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Burmester, Gerd $u Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany.
- 700 1_
- $a Chatzidionysiou, Katerina $u Rheumatology Department, Karolinska Institute, Stockholm, Sweden.
- 700 1_
- $a Dougados, Maxime $u Rhumatologie B, Hopital Cochin, Paris, France.
- 700 1_
- $a Nam, Jackie $u NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
- 700 1_
- $a Ramiro, Sofia $u Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Voshaar, Marieke $u Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands.
- 700 1_
- $a van Vollenhoven, Ronald $u Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands. Zuyderland Medical Center, Heerlen, The Netherlands.
- 700 1_
- $a Aletaha, Daniel $u Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. $7 gn_A_00003878
- 700 1_
- $a Aringer, Martin $u Division of Rheumatology, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. $7 gn_A_00008479
- 700 1_
- $a Boers, Maarten $u Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Buckley, Chris D $u Birmingham NIHR Wellcome Trust Clinical Research Facility, Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.
- 700 1_
- $a Buttgereit, Frank $u Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany.
- 700 1_
- $a Bykerk, Vivian $u Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA. Rebecca McDonald Center for Arthritis & Autoimmune Disease, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- 700 1_
- $a Cardiel, Mario $u Centro de Investigación Clínica de Morelia SC, Michoacán, México.
- 700 1_
- $a Combe, Bernard $u Rheumatology Department, Lapeyronie Hospital, Montpellier University, UMR 5535, Montpellier, France.
- 700 1_
- $a Cutolo, Maurizio $u Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy.
- 700 1_
- $a van Eijk-Hustings, Yvonne $u Department of Patient & Care and Department of Rheumatology, University of Maastricht, Maastricht, The Netherlands.
- 700 1_
- $a Emery, Paul $u Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Finckh, Axel $u Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland.
- 700 1_
- $a Gabay, Cem $u Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland.
- 700 1_
- $a Gomez-Reino, Juan $u Fundación Ramón Dominguez, Hospital Clinico Universitario, Santiago, Spain.
- 700 1_
- $a Gossec, Laure $u Department of Rheumatology, Sorbonne Universités, Pitié Salpêtrière Hospital, Paris, France.
- 700 1_
- $a Gottenberg, Jacques-Eric $u Institut de Biologie Moléculaire et Cellulaire, Immunopathologie, et Chimie Thérapeutique, Strasbourg University Hospital and University of Strasbourg, CNRS, Strasbourg, France.
- 700 1_
- $a Hazes, Johanna M W $u Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- 700 1_
- $a Huizinga, Tom $u Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands.
- 700 1_
- $a Jani, Meghna $u Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.
- 700 1_
- $a Karateev, Dmitry $u V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
- 700 1_
- $a Kouloumas, Marios $u European League Against Rheumatism, Zurich, Switzerland. Cyprus League against Rheumatism, Nicosia, Cyprus.
- 700 1_
- $a Kvien, Tore $u Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
- 700 1_
- $a Li, Zhanguo $u Department of Rheumatology and Immunology, Beijing University People's Hospital, Beijing, China.
- 700 1_
- $a Mariette, Xavier $u Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, INSERM U1184, Center for Immunology of viral Infections and Autoimmune Diseases (IMVA), Le Kremlin Bicêtre, France.
- 700 1_
- $a McInnes, Iain $u Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
- 700 1_
- $a Mysler, Eduardo $u Organización Médica de Investigación, Buenos Aires, Argentina.
- 700 1_
- $a Nash, Peter $u Department of Medicine, University of Queensland, Queensland, Australia.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology and Clinic of Rheumatology, Charles University, Prague, Czech Republic.
- 700 1_
- $a Poór, Gyula $u National Institute of Rheumatology and Physiotherapy, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Richez, Christophe $u Rheumatology Department, FHU ACRONIM, Pellegrin Hospital and UMR CNRS 5164, Bordeaux University, Bordeaux, France.
- 700 1_
- $a van Riel, Piet $u Department of Rheumatology, Bernhoven, Uden, The Netherlands.
- 700 1_
- $a Rubbert-Roth, Andrea $u University of Cologne, Cologne, Germany.
- 700 1_
- $a Saag, Kenneth $u Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- 700 1_
- $a da Silva, Jose $u Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra Praceta Mota Pinto, Coimbra, Portugal.
- 700 1_
- $a Stamm, Tanja $u Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Takeuchi, Tsutomu $u Keio University School of Medicine, Keio University Hospital, Tokyo, Japan.
- 700 1_
- $a Westhovens, René $u Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium. Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.
- 700 1_
- $a de Wit, Maarten $u Department Medical Humanities, VU Medical Centre, Amsterdam, The Netherlands.
- 700 1_
- $a van der Heijde, Désirée $u Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- 773 0_
- $w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 6 (2017), s. 960-977
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28264816 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171030103901 $b ABA008
- 999 __
- $a ok $b bmc $g 1254578 $s 992012
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 76 $c 6 $d 960-977 $e 20170306 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
- LZP __
- $a Pubmed-20171025
